Regenicin, Inc., is a biotechnology company specializing in the development
of regenerative cell therapies to restore the health of damaged tissues and organs.
Regenicin is playing a critical role in the development of the therapeutic candidate, PermaDerm™, an exciting breakthrough technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.
Regenicin Senior Management presents vision and direction at NASDAQ Markets...